Forest CEO: Aptalis a `Compelling Opportunity'
Jan. 8 (Bloomberg) -- Brent Saunders, chief executive officer of Forest Laboratories Inc., talks about the company's agreement to acquire Aptalis Pharma for $2.9 billion in cash. Aptalis is a closely held company whose shareholders include investment firm TPG Capital. Saunders speaks with Betty Liu on Bloomberg Television's "In the Loop." (Source: Bloomberg)
Most Recent Videos
Is Brexit Aftermath Pointing Towards U.K. Recession?
49:38 - Euro-area economic confidence unexpectedly improved in July in a sign that the immediate impact on growth of Britain’s surprise vote to leave the European Union may be muted. An index of business and consumer confidence rose to 104.6 in July from 104.4 the previous month, the European Commission in Brussels said on Thursday. Economists in a Bloomberg survey predicted a decline to 103.5. HSBC Global Chief Economist Janet Henry discusses with Bloomberg's Mark Barton on "The Pulse."